College of Pharmacy, Sookmyung Women's University, Cheongpa-dong 2-ga, Yongsan-gu, Seoul 140-742, Korea.
Nutr Res Pract. 2010 Oct;4(5):393-9. doi: 10.4162/nrp.2010.4.5.393. Epub 2010 Oct 26.
Enteral nutritional support has been used via tube feeding for dysphagic stroke patients. We performed long and short term trials to evaluate the effects of commercial enteral nutritional supports on nutrition and health in stroke patients (mRS = 3~5) and quality of life in their caregivers. For a long term study, we recruited chronic (≥ 1 yrs) stroke patients (n = 6) and administered them 6 cans/day (1,200 kcal) of the commercial enteral formula N for 6 months according to IRB-approved protocol. We collected peripheral blood at 0, 2, 4 and 6 months. For a short term study, we recruited acute (≤ 3 months) stroke patients (n = 12) and randomly administered them two different commercial enteral formulas, N or J, for 2 weeks. We collected their blood at 0, 4, 7 and 14 day of the administration. Blood samples were analyzed to quantify 19 health and nutritional biomarkers and an oxidative stress biomarker, malondialdehyde (MDA). In order to evaluate quality of life, we also obtained the sense of competence questionnaire (SCQ) from all caregivers at 'before' and 'after trials'. As results, the enteral formula, N, improved hemoglobin and hematocrit levels in the long term trial and maintained most of biomarkers within normal ranges. The SCQ levels of caregivers were improved in the long term treatment (P < 0.05). In a case of the short term study, both of enteral formulas were helpful to maintain nutritional status of the patients. In addition, MDA levels were decreased in the acute patients following formula consumption (0.05 < P < 0.1). Most of health and nutrition outcomes were not different, even though there is a big difference in price of the two products. Thus, we evaluate the formula N has equal nutritional efficacy compared to the formula J. In addition, long term use of enteral formula N can be useful to health and nutrition of stroke patients, and the quality of life for their caregivers.
经口进食困难的脑卒中患者可采用管饲进行肠内营养支持。我们进行了长期和短期试验,以评估商业肠内营养支持对脑卒中患者(mRS = 3~5)的营养和健康状况以及其照料者生活质量的影响。在一项长期研究中,我们招募了慢性(≥ 1 年)脑卒中患者(n = 6),并根据 IRB 批准的方案,给予他们每天 6 罐(1200 千卡)的商业肠内配方 N,持续 6 个月。我们在 0、2、4 和 6 个月时采集外周血。在一项短期研究中,我们招募了急性(≤ 3 个月)脑卒中患者(n = 12),并随机给予他们两种不同的商业肠内配方 N 或 J,持续 2 周。我们在给药的第 0、4、7 和 14 天采集他们的血液。分析血液样本以定量测定 19 种健康和营养生物标志物以及氧化应激生物标志物丙二醛(MDA)。为了评估生活质量,我们还从所有照料者在“试验前”和“试验后”获得了能力感问卷(SCQ)。结果,肠内配方 N 在长期试验中提高了血红蛋白和血细胞比容水平,并维持了大多数生物标志物在正常范围内。长期治疗后,照料者的 SCQ 水平提高(P < 0.05)。在短期研究中,两种肠内配方都有助于维持患者的营养状况。此外,配方消耗后急性患者的 MDA 水平降低(0.05 < P < 0.1)。尽管两种产品的价格差异很大,但大多数健康和营养结果没有差异。因此,我们评估配方 N 与配方 J 具有同等的营养功效。此外,长期使用肠内配方 N 可能对脑卒中患者的健康和营养以及其照料者的生活质量有益。